Evidence map›Paper›PMID 39751847›Full record

ArticleCancer immunology, immunotherapy : CII2025

Prognostic relevance of CD163

Ida Lindberg, Aya Saleh, Julia Tutzauer, Frida Björk Gunnarsdottir, Lisa Rydén, Caroline Bergenfelz, Anna-Maria Larsson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ida LindbergDepartment of Translational Medicine, Division of Experimental Infection Medicine, Lund University, 221 84, Lund, Sweden.
Aya SalehDepartment of Translational Medicine, Division of Experimental Infection Medicine, Lund University, 221 84, Lund, Sweden.
Julia TutzauerDepartment of Clinical Sciences Lund, Division of Oncology, Lund University, 221 84, Lund, Sweden.
Frida Björk GunnarsdottirDepartment of Translational Medicine, Division of Experimental Infection Medicine, Lund University, 221 84, Lund, Sweden.
Lisa RydénDepartment of Clinical Sciences Lund, Division of Oncology, Lund University, 221 84, Lund, Sweden.
Caroline BergenfelzDepartment of Translational Medicine, Division of Experimental Infection Medicine, Lund University, 221 84, Lund, Sweden. caroline.bergenfelz@med.lu.se.ORCID http://orcid.org/0000-0001-9337-7285
Anna-Maria LarssonDepartment of Clinical Sciences Lund, Division of Oncology, Lund University, 221 84, Lund, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic breast cancer (MBC) is generally considered an incurable disease and even though new treatments are available, the median survival is approximately three years. The introduction of immune therapies for MBC highlights the importance of the immune system in cancer progression and treatment. CD163

Indexed as

Antigens, CDAntigens, Differentiation, MyelomonocyticBreast NeoplasmsReceptors, Cell SurfaceAdultAgedAged, 80 and overBiomarkers, TumorCD163 AntigenFemaleHumansMiddle AgedNeoplasm MetastasisPrognosisTumor-Associated MacrophagesAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkers, TumorCD163 AntigenReceptors, Cell SurfaceCD163Metastatic breast cancerMyeloid cellsPrognosisTumor-associated macrophages

Identifiers

PMID39751847
PMCPMC11699000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.